NuCana (NCNA) Projected to Post Quarterly Earnings on Thursday

NuCana (NASDAQ:NCNA) will likely be announcing its resultson Thursday, November 12th. Analysts expect the company to announce earnings of ($2.6522) per share for the quarter.

NuCana (NASDAQ:NCNA) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($2.65) by $1.66.

NuCana Stock Performance

NASDAQ NCNA opened at $0.96 on Tuesday. NuCana has a 1-year low of $0.90 and a 1-year high of $4.55. The business has a 50 day simple moving average of $1.17 and a two-hundred day simple moving average of $1.69.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has an average rating of “Sell”.

About NuCana

NuCana plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company uses its ProTide technology to create nucleotide analog medicines designed to improve the delivery and activity of existing chemotherapy agents while addressing mechanisms that can limit treatment effectiveness.

NuCana’s development portfolio has included NUC-1031, also known as Acelarin, a ProTide form of gemcitabine evaluated in several solid tumors. The company has also advanced NUC-3373, a ProTide-based fluoropyrimidine designed to deliver the active component of 5-fluorouracil, and NUC-7738, an investigational cancer therapy based on a nucleoside analog.